Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by cholestasis and, in later stages, cirrhosis. While there is no cure, treatments aim to slow disease progression and reduce the need for liver transplantation. Ursodeoxycholic acid (UDCA) remains the cornerstone therapy due to its proven efficacy and safety. Obeticholic acid (Intercept’s Ocaliva) was previously used in UDCA-intolerant or non-responsive patients but was withdrawn from the U.S. market in September 2025 due to serious liver safety concerns. Emerging therapies like PPAR agonists—Ipsen’s Iqirvo (elafibranor) and Gilead’s Livdelzi (seladelpar)—offer improved outcomes but do not address the underlying autoimmune pathology or significantly alleviate symptoms. This analysis of U.S. patient-level claims data, collected through Q1 2025, explores the use of key PBC therapies, including numerous symptomatic treatments, in both newly diagnosed and recently treated patients, providing insight into the PBC treatment paradigm.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PBC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PBC patients?
• How have UDCA and Ocaliva been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of PBC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of PBC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Content highlights

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Ursodeoxycholic acid, obeticholic acid, elafibranor, seladelpar, fibrates, oral corticosteroids, SSRIs, statins, oral immunosuppressants

Key analyses

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses